CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Werner Enterprises

CureVac's (CVAC) CEO Franz-Werner Haas on Q3 2021 Results - Earnings Call Transcript

Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review Nature publication of promising pre-clinical results for second-generation COVID-19 vaccine candidate, CV2CoV, in study with Harvard Medical School, showing comparable immune response to a licensed mRNA vaccine Positive developments across rest of the pipeline, including pre-clinical results in molecular therapies and progress of Phase 1 study with lead candidate in oncology Re-allocation of existing manufacturing lines and capacities to support second-generation program and streamlining of external manufacturing network Cash position of €1.06 billion as of September 30, 2021. CureVac continues to assess supplier commitments related to the withdrawal of first-generation COVID-19 vaccine candidate CureVac will host a webcast and conference call on Friday, November 19, 2021, at 8 a.m.

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline Plc (NYSE: GSK), in the journal Nature.  Related Link:   CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study.

CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study

TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature.

CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

Shares of CureVac CVAC, -5.65% gained 3.5% in premarket trading on Wednesday after the company shared what it called promising data for its experimental cancer shot in a Phase 1 clinical trial. The injection is being tested in 58 patients with advanced cutaneous melanoma, adenoid cystic carcinoma, and certain types of squamous cell carcinoma as part of the early-stage, open-label study.

CureVac cites 'promising' data for its investigational cancer injection

- Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions - Expansion part of Phase 1 study fully recruited; results expected in the second half of 2022 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced promising data from the completed dose-escalation part of the Phase 1 clinical trial of CV8102, the company's lead oncology candidate.

CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response

CureVac BV (NASDAQ: CVAC) shares are trading lower after the company and Bayer reportedly terminated their vaccine manufacturing partnership. More news came around 1:20 pm EDT after an SEC filing showed that dievini Hopp BioTech holding, which holds roughly 42% of outstanding CureVac shares, plans to sell some of its shares.

Why CureVac Shares Are Falling

The company is throwing in the towel on its first-generation COVID-19 vaccine candidate.

Why CureVac Stock Is Tumbling Today

CureVac NV (NASDAQ: CVAC) is trading lower Tuesday after the company announced it will focus its COVID-19 vaccine development towards the development of second-gen mRNA vaccine candidates in collaboration with GSK and to withdraw its first-gen vaccine from EMA approval process. CureVac estimates that the earliest potential approval of its first-gen vaccine would come in the second quarter of 2022.

Why CureVac Shares Are Trading Lower Today

CureVac is halting development of its first messenger RNA-based Covid-19 vaccine. The news triggered a dive in the stock.

CureVac Drops Its First mRNA-Based Covid Vaccine, and the Stock Is Tumbling

- COVID-19 vaccine efforts to be re-allocated to accelerate the development of second-generation program in collaboration with GSK - First-generation vaccine candidate, CVnCoV, to be withdrawn from regulatory review due to potential overlap with approval timelines for a second-generation candidate TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 12, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).

CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology

Shares of CureVac CVAC, -1.37% tumbled 9.6% in premarket trading on Tuesday after the German biopharmaceutical company said it will scrap development of its COVID-19 vaccine candidate and instead focus on developing second-generation mRNA shots against COVID-19 with GlaxoSmithKline GSK, -1.21% . The existing purchase agreement with the European Commission is no longer in place.

CureVac stops development of its COVID-19 shot, will focus on new COVID-19 vaccine set for 2022

Moderna

Novavax

Vaxart

Today, vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this sector. The post Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today appeared first on InvestorPlace.

Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today

CureVac BV (NASDAQ: CVAC) has canceled contract manufacturing deals for its experimental COVID-19 vaccine with two prospective partners. The Company would terminate agreements with Celonic Group and Wacker, but existing production deals with Rentschler Biopharma and Novartis AG (NYSE: NVS) would remain unchanged.

CureVac Shares Fall After Cutting COVID-19 Vaccine Production Plans

CureVac (NASDAQ:CVAC) shares are trading lower after the company announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pipeline. The decision was made in response to the reduced short-term peak demand for vaccines.

Why CureVac's Stock Is Down During Today's Session

CureVac said it is canceling deals with two companies it had contracted to manufacture its experimental Covid-19 vaccine.

CureVac Stock Falls as Company Cancels Vaccine Manufacturing Contracts

Could CureVac's Canceled Deal Spell Trouble for Other mRNA Cancer Vaccines?

CureVac and partner GlaxoSmithKline say CureVac's second-generation Covid-19 vaccine was more effective than its first in a test with monkeys. CureVac's first vaccine was a disappointment.

CureVac Says Second Covid-19 Vaccine Was Better in Preclinical Test

CureVac NV (NASDAQ: CVAC) disclosed among the COVID-19 vaccine highlights that €465 million oncology partnership with Boehringer Ingelheim had been terminated. CureVac and Boehringer had been working to develop the mRNA cancer vaccine candidate since 2014, when CureVac received about €35 million upfront and nearly €430 million in promised milestones.

Boehringer Ingelheim Scraps Lung Cancer Program With CureVac

BioNTech SE

Today, investors in vaccine stocks are seeing a lot of red, as investors seem to be taking some risk off the table ahead of Fed tapering. The post Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today appeared first on InvestorPlace.

Vaccine Stocks: The Latest News Moving BNTX, CVAC, NVAX Stocks Today

Shares of CureVac N.V. CURE, +0.48% gained 0.4% in morning trading Monday, but bucked the selloff in the biotechnology sector and the broader stock market, after the Germany-based company revealed upbeat preclinical data regarding its vaccine candidates against the coronavirus that causes COVID-19, in non-human primates.

CureVac stock gains after upbeat preclinical data on COVID-19 vaccine candidate on primates

The shares of CureVac N.V. (Nasdaq: CVAC) increased by over 8% pre-market.

CureVac Shares Increase Over 8% Pre-Market: Why It Happened

CureVac aims to become one of Europe's big suppliers.

Can CureVac Win Market Share With Only 48% Vaccine Efficacy?

Funds will not be safe if invested in this coronavirus stock.

Here's Why You Should Avoid CureVac Stock Like the Plague

CureVac shares have slipped more than 20% on bad news.

News for CureVac B.V Stock (CVAC)